Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00362479 · ClinicalTrials.gov registry record · Phase 3
Open-Label Study to Evaluate the Safety and Efficacy of a Low-Dose 28-Day Oral Contraceptive
A Phase 3 study, sponsored by Duramed Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,347
- Enrollment target
NCT00362479 is a Phase 3 study that has completed, run by Duramed Research. The registered enrollment target is 1,347 participants.
The verdict
NCT00362479, a Phase 3 study, has completed, sponsored by Duramed Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,347 participants
- Enrollment target
Study Summary
This is an open-label, single treatment study. All subjects will receive 6 months of oral contraceptive therapy with DR-1021. Study participants will receive physical and gynecological exams, including Pap smear. During the study, all participants will be required to complete a diary.
Interventions
- DRUG DR-1021
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,347 participants |
| Start Date | 2006-08 |
| Est. Completion | 2007-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00362479
The ClinicalTrials.gov registry entry for NCT00362479 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,347 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duramed Research, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DR-1021 is the first listed.
NCT00362479 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00362479 about?
NCT00362479 is a clinical study titled "Open-Label Study to Evaluate the Safety and Efficacy of a Low-Dose 28-Day Oral Contraceptive". This is an open-label, single treatment study. All subjects will receive 6 months of oral contraceptive therapy with DR-1021. Study participants will receive physical and gynecological exams, including Pap smear. During the study, all participants will be required to complete a diary.
What is the current status of trial NCT00362479?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,347 participants. The study started on 2006-08. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00362479?
The interventions under investigation include: DR-1021 (DRUG).
Who is sponsoring clinical trial NCT00362479?
This trial is sponsored by Duramed Research, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.